Higher IMA and IMA + NDI C<sub>min</sub> and higher risks of PD were observed in C allele carriers of rs2231137 and A allele carriers of rs2725252 in <i>ABCG2</i> and in G allele carriers of rs2631372 in <i>SLC22A5.</i> In conclusion, the IMA and IMA + NDI C<sub>min</sub> can serve as effective indicators of advanced GIST treatment outcomes. This evidence concerns the gene SLC22A5 and gastrointestinal stromal tumor.